Daniel Dornbusch

Company: Excision BioTherapeutics

Job title: Chief Executive Officer

Seminars:

11:30AM Maximizing Clinical Trial Success with the Advantages of Generic Assays for Consistency & Accuracy 11:30 am

• Discuss the potential benefits of adopting standardized assays across trials, such as improved data comparability, streamlined regulatory review, and reduced development timelines • Share examples where generic assays have facilitated advancements in therapy evaluation or approval • Address challenges in ensuring that standardized assays remain relevant across different therapeutic areasRead more

day: Conference Day 2

9:00AM Keynote Panel: Gene Therapy Immunogenicity: Challenges, Innovations & the Road to Safe & Effective Therapies 9:00 am

• Overview of recent advancements in gene therapy, focusing on immunogenicity as a critical bottleneck in development and clinical success • Novel tools for immunogenicity assessment, including predictive modeling, biomarkers, and innovative vector designs to minimize immune responses • Collaborative strategies to overcome immunogenicity challenges, streamline regulatory approvals, and deliver safe and effective therapies to…Read more

day: Conference Day 1